title: Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor.
abstract: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited disease characterized by adrenergically mediated polymorphic ventricular tachycardia leading to syncope and sudden cardiac death. The autosomal dominant form of CPVT is caused by mutations in the RyR2 gene encoding the cardiac isoform of the ryanodine receptor. In vitro functional characterization of mutant RyR2 channels showed altered behavior on adrenergic stimulation and caffeine administration with enhanced calcium release from the sarcoplasmic reticulum. As of today no experimental evidence is available to demonstrate that RyR2 mutations can reproduce the arrhythmias observed in CPVT patients. We developed a conditional knock-in mouse model carrier of the R4496C mutation, the mouse equivalent to the R4497C mutations identified in CPVT families, to evaluate if the animals would develop a CPVT phenotype and if beta blockers would prevent arrhythmias. Twenty-six mice (12 wild-type (WT) and 14RyR(R4496C)) underwent exercise stress testing followed by epinephrine administration: none of the WT developed ventricular tachycardia (VT) versus 5/14 RyR(R4496C) mice (P=0.02). Twenty-one mice (8 WT, 8 RyR(R4496C), and 5 RyR(R4496C) pretreated with beta-blockers) received epinephrine and caffeine: 4/8 (50%) RyR(R4496C) mice but none of the WT developed VT (P=0.02); 4/5 RyR(R4496C) mice pretreated with propranolol developed VT (P=0.56 nonsignificant versus RyR(R4496C) mice). These data provide the first experimental demonstration that the R4496C RyR2 mutation predisposes the murine heart to VT and VF in response caffeine and/or adrenergic stimulation. Furthermore, the results show that analogous to what is observed in patients, beta adrenergic stimulation seems ineffective in preventing life-threatening arrhythmias.
authors.affiliation: Molecular Cardiology, IRCCS Fondazione S. Maugeri, Pavia, Italy.
authors.forename: Marina
authors.initials: M
authors.lastname: Cerrone
authors.forename: Barbara
authors.initials: B
authors.lastname: Colombi
authors.forename: Massimo
authors.initials: M
authors.lastname: Santoro
authors.forename: Marina Raffaele
authors.initials: MR
authors.lastname: di Barletta
authors.forename: Mario
authors.initials: M
authors.lastname: Scelsi
authors.forename: Laura
authors.initials: L
authors.lastname: Villani
authors.forename: Carlo
authors.initials: C
authors.lastname: Napolitano
authors.forename: Silvia G
authors.initials: SG
authors.lastname: Priori
mesh_terms: D000818:Animals; D002110:Caffeine / Q000494:pharmacology; D004195:Disease Models, Animal; D004562:Electrocardiography; D004837:Epinephrine / Q000494:pharmacology; D051379:Mice; D009154:Mutation; D019837:Ryanodine Receptor Calcium Release Channel / Q000235:genetics*; D017180:Tachycardia, Ventricular / Q000235:genetics* / Q000517:prevention & control; D014693:Ventricular Fibrillation / Q000235:genetics* / Q000517:prevention & control
chemical_list: D019837:Ryanodine Receptor Calcium Release Channel; D002110:Caffeine; D004837:Epinephrine